Top 20 Drugs Heading for the Patent Cliff, 2026-2029
Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.
The biopharma industry is facing a significant challenge as longtime blockbuster drugs are about to lose their patents, resulting in an estimated $230 billion in annual sales loss.
The idea of a “patent cliff” wave of exclusivity expirations shaking up the biopharma industry isn’t new.
The term "patent cliff" was first mentioned by GEN in 2010, and again in 2011 when Lipitor (atorvastatin) lost its basic U.S. patent. The Economist also used the phrase as early as 2009.
Author's summary: Biopharmas face $230B loss.
- Lipitor (atorvastatin) lost its basic U.S. patent in 2011.
- The Economist described the phenomenon as a “looming patent-expiry crisis” in 2008.
More News
- Jay Glazer says Eagles won't trade A.J. Brown, are interested in Jaelan Phillips | NorthPennNow
- Can the World Health Organization still be the World’s health conscience? -1 | The cracks in global trust
- Israeli Army Abducts Palestinian Father and Son Near Hebron
- Barcelona v Elche live: La Liga text updates, stats, goals
- A Grip on Sports: In both instances it took a lot longer than it should have but there were a couple clear winners Monday
- The chain-ging streets of Bristol: how are independent businesses keeping up?
- Clare-Based ASTI President Says High Income Households Shouldn't Be Exempt From Exam Fees - Clare FM
- University of Alabama Investigating Alleged Incident Involving Dre Kirkpatrick Jr.
- Can the World Health Organization still be the World’s health conscience? - 2 | A house built on donor sand
- Left's Assault on Law Undermines America's Justice System